7SS Stock Chart & Stats
€0.19
<€0.01(7.63%)
At close: 4:00 PM EST
€0.19
<€0.01(7.63%)
Day’s Range― - ―
52-Week Range€0.09 - €0.26
Previous CloseN/A
Volume0.00
Average Volume (3M)42.00
Market Cap
€73.62M
Enterprise Value-€1.40K
Total Cash (Recent Filing)€1.77B
Total Debt (Recent Filing)€6.18M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding734,958,250
10 Day Avg. Volume0
30 Day Avg. Volume42
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.38
Price to Sales (P/S)50.44
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityVery low leverage reduces financial risk and preserves flexibility as Brii funds development and commercialization. Positive equity provides a cushion against operating losses and gives management more room to allocate capital without the immediate pressure of heavy debt obligations.
Improved 2025 Losses And Cash BurnThe improvement in losses and cash burn during 2025 indicates some progress in financial control, even though the company remains unprofitable. If sustained, lower resource consumption could extend liquidity and create more time for partnered or marketed products to contribute.
Partner-led Product ModelA partner-led model can provide access to externally originated therapies while sharing development and commercialization responsibilities. Collaboration and licensing arrangements may also create milestone, royalty, or cost-sharing opportunities without requiring Brii to build every asset internally.
Bears Say
Persistent Cash BurnPersistent negative operating and free cash flow means the business is not yet funding its activities internally. Continued cash burn can require external financing or use of existing liquidity, potentially limiting investment capacity and increasing pressure to monetize products or partnerships.
Sustained UnprofitabilityOngoing losses and deeply negative margins show that the current operating model has not reached sustainable profitability. Without durable margin improvement, future revenue or partnership gains may continue to be absorbed by development and operating costs rather than building recurring earnings.
Sharp Revenue ContractionA sharp revenue decline weakens evidence of scalable commercial traction and makes the company more dependent on individual products or partnership events. Continued volatility can complicate planning, reduce operating leverage, and delay the path toward a stable recurring revenue base.
Brii Biosciences Limited News
7SS FAQ
What was Brii Biosciences Limited’s price range in the past 12 months?
Brii Biosciences Limited lowest stock price was €0.09 and its highest was €0.26 in the past 12 months.
What is Brii Biosciences Limited’s market cap?
Brii Biosciences Limited’s market cap is €73.62M.
When is Brii Biosciences Limited’s upcoming earnings report date?
Brii Biosciences Limited’s upcoming earnings report date is Mar 19, 2027 which is in 189 days.
How were Brii Biosciences Limited’s earnings last quarter?
Brii Biosciences Limited released its earnings results on Aug 20, 2026. The company reported -€0.018 earnings per share for the quarter, missing the consensus estimate of -€0.014 by -€0.004.
Is Brii Biosciences Limited overvalued?
According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued.
Does Brii Biosciences Limited pay dividends?
Brii Biosciences Limited does not currently pay dividends.
What is Brii Biosciences Limited’s EPS estimate?
Brii Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brii Biosciences Limited have?
Brii Biosciences Limited has 734,958,250 shares outstanding.
What happened to Brii Biosciences Limited’s price movement after its last earnings report?
Brii Biosciences Limited reported an EPS of -€0.018 in its last earnings report, missing expectations of -€0.014. Following the earnings report the stock price went up 5.155%.
Which hedge fund is a major shareholder of Brii Biosciences Limited?
Currently, no hedge funds are holding shares in DE:7SS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brii Biosciences Limited
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
Technical Analysis
Mabpharm Limited
―
Clover Biopharmaceuticals Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Transcenta Holding Limited
―
AIM Vaccine Co., Ltd. Class H
―